Recent Headlines
SignaBlok Awarded NIH NIDDK Grant to Develop Novel TREM-1 Antagonist Drug for Inflammatory Bowel Disease
SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD. - September 18, 2026 - SignaBlok, Inc.
Rob Merrill Named CEO of TFives, Life Sciences AI Compliance
TFives appoints 25-year healthcare regulatory veteran as CEO to lead enterprise adoption of compliance-ready AI governance for the Life Sciences industry. - September 17, 2026 - TFives
Microvascular Therapeutics Appoints George Kokke to Board of Directors
Veteran family office executive and healthcare investor brings more than 30 years of investment, finance, and board experience. - September 17, 2026 - Microvascular Therapeutics, Inc.
The Rare Cancer That Can Return Decades Later Brings Patients Together to Launch the Solitary Fibrous Tumor Foundation
The Solitary Fibrous Tumor Foundation (SFTF) today announced its launch as the first patient- and supporter-led nonprofit organization dedicated entirely to Solitary Fibrous Tumor (SFT), an ultra-rare sarcoma.The announcement comes during Sarcoma Awareness Month, observed globally each July. SFT... - September 17, 2026 - Solitary Fibrous Tumor Foundation
Microvascular Therapeutics Appoints Charles Garrison, MD, to Scientific Advisory Board
Dr Charles Garrison, an experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development as new Scientific Advisory Board member. - September 14, 2026 - Microvascular Therapeutics, Inc.
MVT Nanobubbles Enable Non-Thermal Focused Ultrasound Ablation in Preclinical Brain Tumor Study
University of Utah researchers use MVT-101 phase-shift nanobubbles with focused ultrasound and MRI to confirm treatment location - September 14, 2026 - Microvascular Therapeutics, Inc.
Kepon Biotech Addresses Global Biopharma Supply‑Chain Pain Points with China‑Based One‑Stop Procurement System
Kepon Biotech is a Chinese one‑stop supply‑chain partner for life‑science clients. It resolves procurement challenges: scattered suppliers, complex cross‑border compliance, variable batch quality and long lead‑times. It provides consolidated sourcing, special‑goods compliance, graded cold‑chain logistics and global certifications for cell lines, culture media, LAL reagents and clinical materials, delivering streamlined, low‑risk procurement for pharma, IVD, CRO/CDMO and research institutes. - September 07, 2026 - Shanghai Kepon Biotech Co., Ltd.
Asclepii Selected to Exhibit Poseidon at Vizient Innovative Technology Exchange
Asclepii will showcase its FDA 510(k)-cleared Poseidon™ Nanosilver Hydrogel at Vizient’s Innovative Technology Exchange in Las Vegas on September 24, marking an important milestone in the company’s commercial expansion and bringing its wound care technology to healthcare leaders across Vizient’s network. - September 04, 2026 - Asclepii
VMRD Launches Rapid Horse-Side Insulin Test to Decrease Risk of Laminitis in Metabolic Horses
VMRD, Inc. is thrilled to share the launch of their exciting new test for horse-side measurement of insulin in horses. Run on the same palm-sized reader as VMRD SAA and Foal IgG, this highly portable multi-functional testing platform embodies VMRD’s vision of improving animal health through... - August 28, 2026 - VMRD, Inc.
Kepon Biotech Launches Integrated Cross‑Border Risk‑Control Solutions for Global Cell Culture Media Trade
Kepon Biotech handles import‑export for fermentation, research and GMP clinical‑grade cell culture media. It addresses cross‑border risks such as bioactivity degradation, complex global regulations and customs detention. With EAC, REACH, FDA, TGA, PMDA, CMDCAS and Halal credentials, it delivers grade classification, global certification, light‑shielded cold‑chain logistics and multilingual customs documents for global CDMOs, biomanufacturers and research labs. - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross‑Border Solutions for Global Spermidine Procurement
Kepon Biotech provides multi‑grade spermidine and spermidine trihydrochloride for food, pharma, cosmetics and life‑science research. It mitigates cross‑border risks such as oxidative degradation, complex certification rules and HS misclassification. Backed by EAC, REACH, FDA and Halal credentials, it delivers one‑stop certification, nitrogen‑sealed temperature‑controlled logistics and multilingual customs documents for manufacturers, labs and distributors across EAEU, EU, U.S. and Middle‑East. - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches One-Stop Cross-Border Compliance & Logistics Solutions for Life Science Reagents
Kepon Biotech provides a one-stop global compliance and supply system for life science procurement. It solves core cross-border challenges including complex customs clearance, unstable cold-chain logistics, fragmented regional regulations. The company offers standardized biochemical reagents, reference standards and cell culture media, with full compliance support and segmented temperature-controlled logistics, delivering reliable, low-risk sourcing for global labs and pharmaceutical manufacture - August 19, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross‑Border Export Solutions for Global LAL Endotoxin‑Testing Reagent Procurement
Kepon Biotech delivers factory‑sourced LAL endotoxin‑testing kits for biopharma, vaccine and medical‑device clients. Working with ISO13485‑certified manufacturers, it provides regional compliance paperwork, 2‑8°C cold‑chain logistics and low‑MOQ trial orders across CIS, Southeast Asia, Middle East, EU and North America. Its one‑stop export solution fixes customs detention, reagent deactivation and raw‑material stock‑out risks for 1000+ users in 50+ countries. - August 18, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Unveils Full-Link Risk Control & Compliance Solutions for Global Cell Culture Media Trade
Global labs and biopharma firms encounter common cell culture media procurement risks: inconsistent batches, customs delays, cold chain product inactivation and inflexible high MOQs. Shanghai Kepon Biotech releases a full cross-border supply solution and procurement risk guide, offering flexible samples, one-stop biological goods clearance and segmented cryogenic logistics for global cell research, biotech and diagnostic manufacturers. - August 18, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Comprehensive Cross-Border Procurement & Risk Control Solutions for Industrial Fine Chemicals
Global factories, energy plants and research labs run into widespread procurement risks for industrial chemicals: inconsistent purity, hazardous goods customs blockages, failed long-distance shipping, rigid high MOQs and incomplete compliance documents. Shanghai Kepon Biotech releases an integrated cross-border supply system and complete pitfall guide, providing flexible trial orders, one-stop chemical customs agency and dedicated hazardous cold chain logistics for biotech, pharmaceutical. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Kepon Biotech Launches Integrated Cross-Border Procurement and Risk Control Solutions for High-Purity Organic & Inorganic Chemicals
Global labs and pharma face organic & inorganic chemical procurement risks including unstable purity, customs detention, failed shipping, high MOQs and incomplete SDS docs. Shanghai Kepon Biotech releases a cross-border supply & risk guide with flexible samples, full chemical clearance and custom cold chain logistics for life science and new energy industries. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Shanghai Kepon Biotech Launches Full Risk-Control Cross-Border Solutions for Certified Reference Standards Procurement
Global labs, pharma and food testers face China reference standards cross-border risks: poor batch traceability, customs delays, rigid MOQs, cold chain breakdowns and missing COA/SDS. Shanghai Kepon Biotech offers integrated supply, special goods clearance and segmented cold chain for life science, new energy and food testing industries. - August 17, 2026 - Shanghai Kepon Biotech Co., Ltd.
Food Safety Standards Raw Material Procurement Solutions & Risk Avoidance Guide Released by Shanghai Kepon Biotech for Global Food Testing & Food Manufacturing Plants
Global food manufacturers and third-party food testing labs face severe procurement risks for food safety reference standards: inconsistent batch purity, cross-border food regulatory document gaps, strict customs inspection, high MOQ limits and incomplete compliance certification. Shanghai Kepon Biotech launches integrated cross-border supply system, one-stop food safety filing and traceable certified standards for food testing, beverage and food processing industries worldwide. - August 16, 2026 - Shanghai Kepon Biotech Co., Ltd.
New 2026 Report Reveals an AI/LLM Gap Between Biopharma Sponsors and Their CROs/Vendors
Life Science Strategy Group looks beyond frontier-AI hype to show how biopharma teams use AI and LLMs in daily work, and where their CRO and vendor partners are falling short. 71% of sponsors rate their own AI/LLM output highly. Only 27% say the same of their CROs and vendors. - August 12, 2026 - Life Science Strategy Group, LLC
Ferrari and Dr. David Pincus of Pincus Plastic Surgery Unveil a Luxury Lounge Experience at the Hamptons Concours
The roar of rare Ferraris, the unmistakable elegance of the Hamptons, and one of plastic surgery's most recognizable luxury brands came together for an unforgettable weekend at the 2026 Hamptons Concours, produced by luxury event visionary Bradford Rand. Widely regarded as one of the East Coast's... - August 10, 2026 - Pincus Plastic Surgery
Plastic Surgeon Dr. David Pincus Sponsors the Hamptons Concours d’Elegance Supporting the Southampton Animal Shelter Foundation
Plastic Surgeon Dr. David Pincus and Pincus Plastic Surgery proudly sponsored the 2026 Hamptons Concours d'Elegance, one of the Hamptons' premier luxury charity events, bringing together exotic automobiles, luxury brands, community leaders, and philanthropists for a day dedicated to supporting the... - August 06, 2026 - Pincus Plastic Surgery
Minus K Technology Launches It Educational Giveaway for Universities and Colleges in the USA
Minus K Technology announces its 11th Educational Giveaway of passive mechanical vibration isolators for Universities and Colleges within the USA. Winners get a free brand new negative-stiffness vibration isolator to be used at their school. - August 03, 2026 - Minus K Technology Inc.
Microvascular Therapeutics Highlights the Future of Ultrasound Theranostics in Comprehensive Wiley Review
Microvascular Therapeutics, Inc. (MVT) today announced publication of a comprehensive review in Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (WIREs Nanomedicine and Nanobiotechnology), a leading peer-reviewed journal with a 2025 Journal Impact Factor of 8.6, entitled,... - July 28, 2026 - Microvascular Therapeutics, Inc.
Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
Slimshot® recognized in Medical Devices & Technology Concept category; product selected for display at Red Dot Design Museum in Singapore. - July 14, 2026 - Pacto Medical
Validation Management Solutions Expands Leadership Team with the Appointment of Remoun Amin as Partner
Validation Management Solutions (VMS) has appointed Remoun Amin as Partner, marking an important milestone in the company's growth. With more than two decades of life sciences experience, Amin strengthens VMS's ability to deliver expert CQV, calibration, and temperature mapping services while advancing its vision to help clients build assurance that scales with them. - July 09, 2026 - Validation Managment Solutions
Microvascular Therapeutics to Present Late-Breaking Clinical Data on CardiSon™ (MVT-100) at the 2026 American Society of Echocardiography Meeting.
Clinical Study Demonstrates Superior Left Ventricular Opacification and Significantly Reduced Acoustic Shadowing Compared with Definity®. - June 26, 2026 - Microvascular Therapeutics, Inc.
OurJrney Expands Beyond Online Sales and Seeks Retail Distribution Partners Across the United States
Following strong consumer response and growing brand momentum, OurJrney is expanding beyond e-commerce and opening opportunities for retail distributors and influencer partnerships worldwide. - June 24, 2026 - PureJourney Inc
Good Mana and Voyaging Foods Announce Strategic Collaboration to Scale Hawai‘i-Grown Functional Foods and Nutraceuticals
Good Mana and Voyaging Foods announced a strategic collaboration to scale Hawai‘i-grown functional foods and nutraceuticals by transforming crops like turmeric, taro, breadfruit, and sweet potato into shelf-stable wellness products. The partnership aims to reduce food waste, support farmers, preserve nutrients, and make healthy local foods more accessible. - June 19, 2026 - Good Mana
10,000 Customers Finally Found a Turmeric That Works — OurJrney Marks Sales Milestone
The nano-particle absorption breakthrough that made piperine obsolete has now reached 10,000 units sold — with customers pointing to both noticeable results and a taste that sets it apart from traditional turmeric supplements. - June 17, 2026 - PureJourney Inc
OurJrney NeuroMatcha Gives High Performers a Way to Finish The Day as Sharp as They Started
This Daily Cognitive Boost combines premium-grade matcha, Alpha-GPC, and functional mushrooms into a daily cognitive ritual that eliminates the afternoon crash with sustained, calm mental clarity. - June 12, 2026 - PureJourney Inc
While Telehealth Giants Face Federal Scrutiny, Ivia Health Has Been Quietly Getting It Right
Ivia Health, a LegitScript-certified, HIPAA-compliant GLP-1 telehealth platform operating across 40+ U.S. states, is launching Ivia Health Benefits, an employer GLP-1 benefit program built on a certified, compliant foundation. As federal regulators crack down on non-compliant telehealth platforms, Ivia offers employers and patients a transparent, cash-pay alternative built right from day one. - June 11, 2026 - Ivia Health, LLC
Novugen Pharma (USA) LLC Launches ANDA-Approved Everolimus Tablets in the U.S.
Novugen Pharma (USA) LLC has launched Everolimus Tablets 2.5 mg, 5 mg, 7.5 mg, and 10 mg in the U.S. market, following the approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (USFDA) in October 2025, further strengthening Novugen’s presence in a... - June 10, 2026 - Novugen
MyConcussionDR Announces Public Support for the American Center for Cures
Brain health education team joins national initiative to fund the prevention and cure of major diseases, citing its shared commitment to families, accountability, and long-term neurological health. - June 08, 2026 - MyconcussionDR
Alera Bio Appoints David McCullough as Chief Executive Officer
Alera Bio announced the appointment of David McCullough as Chief Executive Officer. An experienced biotechnology executive, McCullough will lead corporate strategy, financing, organizational development, and execution of the company’s clinical and regulatory roadmap. He will oversee advancement of AB-101, Alera’s novel therapy for MCT-8 deficiency, as the company works to bring new hope to patients and families affected by this devastating rare neurodevelopmental disorder. - June 04, 2026 - Alera Bio
Trivelia® Wins "Hair Supplement of the Year" Award
Trivelia® is proud to announce that it has been named "Hair Supplement of the Year 2026 – Norway" in the prestigious Healthcare & Pharmaceuticals Awards 2026, presented by Global Health & Pharma (GHP). - May 15, 2026 - Nordics Co AS
Asclepii Partners with Nottingham Spirk to Scale Breakthrough Regenerative Wound Care Technology Nationwide
Strategic collaboration aims to expand access to next-generation regenerative platform designed to improve healing outcomes and reduce the cost of chronic wound care. - May 06, 2026 - Asclepii
Movanze™ Wins Multiple 2026 Awards – Recognized as a Leading Candidate for “Best Joint Support Supplement” in Europe
Movanze™, a premium joint and muscle support supplement developed in Scandinavia, has been awarded two major industry recognitions in 2026, strengthening its position as a leading contender for the best joint support supplement in both Norway and Europe. - May 05, 2026 - Nordics Co AS
Parvus Therapeutics Initiates First-in-Human Clinical Trial of PVT401 for Inflammatory Bowel Disease
PVT401, a peptide-MHC nanomedicine, is the second Parvus drug candidate to enter clinical trials. - April 30, 2026 - Parvus Therapeutics U.S., Inc.
CalStop™ Named Weight Loss Supplement of the Year 2026
Norwegian-developed supplement recognised for science-aligned approach to appetite control and weight management. - April 23, 2026 - Nordics Co AS
International Vitamin Corporation to Be Featured on Now We Know! with Steve Guttenberg – Airing April 18 on CNBC
The upcoming episode of Now We Know! with SteveGuttenberg, airing April 18 at 11a ET on CNBC, will feature International Vitamin Corporation, a company specializing in the development and manufacturing of vitamins, supplements, and nutritional products. - April 17, 2026 - International Vitamin Corporation
Aldevron Named 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy Category
Aldevron has been recognized as a 2026 CDMO Leadership Awards Winner in the Small/Mid-Size Cell & Gene Therapy category. The CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect, are widely regarded as one of the most credible benchmarks of CDMO performance in the biopharma industry. Now in their 15th year, the awards are based entirely on verified feedback. - April 14, 2026 - Aldevron
International Vitamin Corporation Recognized by Food Business Review as Top Private Label Supplement Manufacturer 2026
International Vitamin Corporation (IVC), a leading global manufacturer of vitamins, minerals, and supplements, has been recognized as the Top Private Label Supplement Manufacturer 2026 by Food Business Review. This recognition reflects IVC’s leadership in accelerating speed-to-market and... - April 13, 2026 - International Vitamin Corporation
Alera Bio Announces Exclusive Licensing Agreement with BLA Technology to Expand Thyroid Hormone Intellectual Property Portfolio
Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. - April 09, 2026 - Alera Bio
Alera Bio Appoints Andrew Eisen, MD, PhD, as Chief Scientific Officer
Alera Bio has appointed Andrew Eisen, MD, PhD, as Chief Scientific Officer, bringing over 20 years of experience in translational medicine and clinical development. With deep expertise in neuroscience, metabolic disease, and myelination, Dr. Eisen will lead the advancement of Alera’s lead program, AB-101, and help drive its mission to develop transformative therapies for patients with severe neurological disorders, including MCT-8 deficiency. - April 08, 2026 - Alera Bio
GENINVO Introduces CodeMagic: AI‑Assisted Code Generation for Statistical Programming
GENINVO, a leading provider of transformative digital solutions for the life sciences sector, proudly announces the launch of CodeMagic, an innovative AI‑assisted coding platform designed to accelerate and simplify statistical programming across clinical research and pharmaceutical... - April 05, 2026 - GenInvo, Inc.
Brain Healing, Inc. Receives FDA Humanitarian Use Device (HUD) Designation for MELAS
Non-invasive biophoton platform advances toward HDE pathway for rare mitochondrial disease - April 01, 2026 - Tesla BioHealing, Inc.
Best Joint Supplement: Movanze™ Wins Award
Best joint supplement is the title Movanze™ has now been awarded in Norway for 2026, after being recognized with the distinction “Best Joint Support Supplement of the Year, Norway 2026” in the Logistics & Supply Chain Awards, conducted by Global Brands Magazine. - March 31, 2026 - Nordics Co AS
SignaBlok Receives Orphan Drug Designation from FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurity
SignaBlok, Inc., a preclinical stage biotechnology company pioneering novel, first-in-class peptide therapies for multiple inflammation-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s TREM-1 peptide... - March 27, 2026 - SignaBlok, Inc.
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
• In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy - March 26, 2026 - SignaBlok, Inc.
Longevity Rx Partners with Equinox Hotels to Bring Clinical-Grade Cellular Health Supplements to Luxury Hospitality
Dr. Will Cole's functional medicine-backed supplement brand joins Equinox Hotels' curated high-performance offering at the flagship Hudson Yards location. - March 17, 2026 - Longevity Rx